Login to Your Account

Reducing Risk in Mega Trials

Biomarkers Helpful but Not Cornucopia for Heart Drugs

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, April 9, 2012

Last month, Anthera Pharmaceuticals Inc.'s Phase III VISTA-16 trial testing varespladib in acute coronary syndrome (ACS) patients was stopped for futility, a surprise considering the robust changes in biomarkers seen in the Phase II trial.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription